QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=AE4F7F7AAFC4068E9F3136CFBA2A254B;jsessionid=081E2E86E96080529C92C4FB5785CA02;jsessionid=648DCC623151EB6C1BD56A89A16DA0B0;jsessionid=F643F417C5B131B05933602EC2510AD7;jsessionid=CC440698C953E6D1B5A86C85FDC8691C;jsessionid=F33CBD3B9AC9F919CB11511C00D8B826;jsessionid=CA6B31AA2A859BE2B2586D422F6B6CC1;jsessionid=A1B117D669BAE3DCB020ABD0FC86065B;jsessionid=1BA48237B25EFF76CE52B8C33B12CFFE (gene)

1. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
2. Missense mutation in ATXN2 gene (c.2860C > T) in an amyotrophic lateral sclerosis patient with aggre…
3. The RNA-binding protein and stress granule component ATAXIN-2 is expressed in mouse and human tissue…
4. Ataxin-2 gene: a powerful modulator of neurological disorders.
5. Antagonistic roles for Ataxin-2 structured and disordered domains in RNP condensation.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=AE4F7F7AAFC4068E9F3136CFBA2A254B;jsessionid=081E2E86E96080529C92C4FB5785CA02;jsessionid=648DCC623151EB6C1BD56A89A16DA0B0;jsessionid=F643F417C5B131B05933602EC2510AD7;jsessionid=CC440698C953E6D1B5A86C85FDC8691C;jsessionid=F33CBD3B9AC9F919CB11511C00D8B826;jsessionid=CA6B31AA2A859BE2B2586D422F6B6CC1;jsessionid=A1B117D669BAE3DCB020ABD0FC86065B;jsessionid=1BA48237B25EFF76CE52B8C33B12CFFE